{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T14:18:47Z","timestamp":1778163527393,"version":"3.51.4"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Implant Dent"],"published-print":{"date-parts":[[2019,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n              <jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Medication-related osteonecrosis of the jaw (MRONJ) is characterized by the development of bone necrosis in the jaws of patients receiving antiresorptive and\/or antiangiogenic medications. No scientific reports have been published yet on bevacizumab-related osteonecrosis of the jaw (BeRONJ) when associated with dental implant placement and adjuvant ozone therapy.<\/jats:p>\n              <\/jats:sec>\n              <jats:sec>\n                <jats:title>Case presentation<\/jats:title>\n                <jats:p>A 54-year-old female patient with a history of metastatic breast cancer and bevacizumab use presented with a dental infection. Dental extraction followed immediately by dental implant placement was planned after suspension of the bevacizumab treatment. The patient presented with pain, drainage of purulent secretion, and bone exposure 5\u2009weeks post-surgery. Complete healing was achieved at postoperative 7\u2009months.<\/jats:p>\n              <\/jats:sec>\n              <jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>The combination of adjuvant ozone therapy and surgical debridement was effective for the treatment of MRONJ; however, the risk of MRONJ may persist after the suspension of bevacizumab for 28\u2009days.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s40729-019-0188-0","type":"journal-article","created":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T02:58:49Z","timestamp":1569898729000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["A rare case of bevacizumab-related osteonecrosis of the jaw associated with dental implants"],"prefix":"10.1186","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5507-1824","authenticated-orcid":false,"given":"Gustavo","family":"Maluf","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rog\u00e9rio Jardim","family":"Caldas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eduardo Rodrigues","family":"Fregnani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paulo S\u00e9rgio","family":"da Silva Santos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,10,1]]},"reference":[{"key":"188_CR1","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1016\/j.oraloncology.2011.03.028","volume":"47","author":"AL Watters","year":"2011","unstructured":"Watters AL, Epstein JB, Agulnik M. Oral complications of targeted cancer therapies: a narrative literature review. Oral Oncol. 2011;47:441\u20138.","journal-title":"Oral Oncol"},{"key":"188_CR2","doi-asserted-by":"publisher","first-page":"4743","DOI":"10.1200\/JCO.2007.12.3026","volume":"25","author":"RS Herbst","year":"2007","unstructured":"Herbst RS, O\u2019Neill VJ, Fehrenbacher L, et al. Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory none small-cell lung cancer. J Clin Oncol. 2007;25:4743\u201350.","journal-title":"J Clin Oncol"},{"key":"188_CR3","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1016\/j.clbc.2011.02.001","volume":"11","author":"N Ngamphaiboon","year":"2011","unstructured":"Ngamphaiboon N, Frustino JL, Kossoff EB, et al. Osteonecrosis of the jaw: dental outcomes in metastatic breast cancer patients treated with bisphosphonates with\/without bevacizumab. Clin Breast Cancer. 2011;11:252\u20137.","journal-title":"Clin Breast Cancer"},{"key":"188_CR4","doi-asserted-by":"publisher","first-page":"4037","DOI":"10.1200\/JCO.2007.15.5424","volume":"26","author":"CL Estilo","year":"2008","unstructured":"Estilo CL, Fornier M, Farooki A, et al. Osteonecrosis of the jaw related to bevacizumab. J Clin Oncol. 2008;26:4037\u20138.","journal-title":"J Clin Oncol"},{"key":"188_CR5","first-page":"74","volume":"10","author":"WJ Starck","year":"1995","unstructured":"Starck WJ, Epker BN. Failure of osseointegrated dental implants after diphosphonate therapy for osteoporosis: a case report. Int J Oral Maxillofac Implants. 1995;10:74\u20138.","journal-title":"Int J Oral Maxillofac Implants"},{"key":"188_CR6","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1007\/s00784-012-0708-2","volume":"17","author":"C Jacobsen","year":"2013","unstructured":"Jacobsen C, Metzler P, R\u00f6ssle M, et al. Osteopathology induced by bisphosphonates and dental implants: clinical observations. Clin Oral Investig. 2013;17:167\u201375.","journal-title":"Clin Oral Investig"},{"key":"188_CR7","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1111\/clr.12088","volume":"25","author":"TG Kwon","year":"2014","unstructured":"Kwon TG, Lee CO, Park JW, et al. Osteonecrosis associated with dental implants in patients undergoing bisphosphonate treatment. Clin Oral Implants Res. 2014;25:632\u201340.","journal-title":"Clin Oral Implants Res"},{"key":"188_CR8","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.1093\/annonc\/mdn653","volume":"19","author":"S Greuter","year":"2008","unstructured":"Greuter S, Schmid F, Ruhstaller T, et al. Bevacizumab-associated osteonecrosis of the jaw. Ann Oncol. 2008;19:2091\u20132.","journal-title":"Ann Oncol"},{"key":"188_CR9","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.1016\/j.joms.2014.04.031","volume":"72","author":"SL Ruggiero","year":"2014","unstructured":"Ruggiero SL, Dodson TB, Fantasia J, et al. American association of oral and maxillofacial surgeons position paper on medication-related osteonecrosis of the jaw-2014 update. J Oral Maxillofac Surg. 2014;72:1938\u201356.","journal-title":"J Oral Maxillofac Surg"},{"key":"188_CR10","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1007\/s00774-016-0810-7","volume":"35","author":"T Yoneda","year":"2017","unstructured":"Yoneda T, Hagino H, Sugimoto T, Ohta H, et al. Antiresorptive agent-related osteonecrosis of the jaw: position paper 2017 of the Japanese Allied Committee on Osteonecrosis of the Jaw. Japanese Allied Committee on Osteonecrosis of the Jaw. J Bone Miner Metab. 2017;35:6\u201319.","journal-title":"J Bone Miner Metab"},{"key":"188_CR11","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1111\/clr.12526","volume":"27","author":"J Ata-Ali","year":"2016","unstructured":"Ata-Ali J, Ata-Ali F, Pe\u00f1arrocha-Oltra D, et al. What is the impact of bisphosphonate therapy upon dental implant survival? A systematic reviewand meta-analysis. Clin Oral Implants Res. 2016;27:38\u201346.","journal-title":"Clin Oral Implants Res"},{"key":"188_CR12","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1111\/j.1600-051X.2012.01854.x","volume":"39","author":"JK Yip","year":"2012","unstructured":"Yip JK, Borrell LN, Cho SC, et al. Association between oral bis- phosphonate use and dental implant failure among middle-aged women. J Clin Periodontol. 2012;39:408\u201314.","journal-title":"J Clin Periodontol"},{"key":"188_CR13","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1007\/s10006-012-0379-9","volume":"17","author":"D Pakosch","year":"2013","unstructured":"Pakosch D, Papadimas D, Munding J, et al. Osteonecrosis of the mandible due to anti-angiogenic agent, bevacizumab. Oral Maxillofac Surg. 2013;17:303\u20136.","journal-title":"Oral Maxillofac Surg"},{"key":"188_CR14","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1111\/clr.12164","volume":"25","author":"S Corbella","year":"2014","unstructured":"Corbella S, Taschieri S, Samaranayake L, Tsesis I, et al. Implant treatment choice after extraction of a vertically fractured tooth. A proposal for a clinical classification of bony defects based on a systematic review of literature. Clin Oral Implants Res. 2014;25:946\u201356.","journal-title":"Clin Oral Implants Res"},{"key":"188_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/cid.12098","volume":"17","author":"BR Chrcanovic","year":"2015","unstructured":"Chrcanovic BR, Martins MD, Wennerberg A. Immediate placement of implants into infected sites: a systematic review. Clin Implant Dent Relat Res. 2015;17:1\u201316.","journal-title":"Clin Implant Dent Relat Res"},{"key":"188_CR16","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1007\/s10549-010-0866-3","volume":"122","author":"V Guarneri","year":"2010","unstructured":"Guarneri V, Miles D, Robert N, et al. Bevacizumab and osteonecrosis of the jaw: incidence and association with bisphosphonate therapy in three large prospective trials in advanced breast cancer. Breast Cancer Res Treat. 2010;122:181\u20138.","journal-title":"Breast Cancer Res Treat"},{"key":"188_CR17","first-page":"196","volume":"16","author":"E Dietrich","year":"2012","unstructured":"Dietrich E, Antoniades K. Molecularly targeted drugs for the treatment of cancer: oral complications and pathophysiology. Hippokratia. 2012;16:196\u201369.","journal-title":"Hippokratia."},{"key":"188_CR18","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1111\/jcpe.12455","volume":"42","author":"E Gaudin","year":"2015","unstructured":"Gaudin E, Seidel L, Bacevic M, et al. Occurrence and risk indicators of medication-related osteonecrosis of the jaw after dental extraction: a systematic review and meta-analysis. J Clin Periodontol. 2015;42:922\u201332.","journal-title":"J Clin Periodontol"},{"key":"188_CR19","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1007\/s00520-017-3629-4","volume":"25","author":"E Vigarios","year":"2017","unstructured":"Vigarios E, Epstein JB, Sibaud V. Oral mucosal changes induced by anticancer targeted therapies and immune checkpoint inhibitors. Support Care Cancer. 2017;25:1713\u201339.","journal-title":"Support Care Cancer"},{"key":"188_CR20","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1111\/j.1600-0501.2011.02172.x","volume":"22","author":"NP Lang","year":"2011","unstructured":"Lang NP, Salvi GE, Huynh-Ba G, et al. Early osseointegration to hydrophilic and hydrophobic implant surfaces in humans. Clin Oral Implants Res. 2011;22:349\u201356.","journal-title":"Clin Oral Implants Res"},{"key":"188_CR21","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1053\/joms.2001.27515","volume":"59","author":"M August","year":"2001","unstructured":"August M, Chung K, Chang Y, et al. Influence of estrogen status on endosseous implant osseointegration. J Oral Maxillofac Surg. 2001;59:1285\u20139.","journal-title":"J Oral Maxillofac Surg"},{"key":"188_CR22","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1111\/clr.13445","volume":"30","author":"M Dantas","year":"2019","unstructured":"Dantas M, Verzola A, Sanit\u00e1 V, et al. The influence of cisplatin-based chemotherapy on the osseointegration of dental implants: an in vivo mechanical and histometrical study. Clin Oral Implants Res. 2019;30:603\u201316.","journal-title":"Clin Oral Implants Res"},{"key":"188_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/JCO.19.01186","volume":"37","author":"N Yarom","year":"2019","unstructured":"Yarom N, Shapiro C, Peterson D, et al. Medication-related osteonecrosis of the jaw: MASCC\/ISOO\/ASCO Clinical Practice Guideline. J Clin Oncol. 2019;37:1\u201321.","journal-title":"J Clin Oncol"},{"key":"188_CR24","doi-asserted-by":"publisher","first-page":"1512","DOI":"10.1093\/annonc\/mdl163","volume":"17","author":"G Sanna","year":"2006","unstructured":"Sanna G, Preda L, Bruschini R, et al. Bisphosphonates and jaw osteonecrosis in patients with advanced breast cancer. Ann Oncol. 2006;17:1512\u20136.","journal-title":"Ann Oncol"},{"key":"188_CR25","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/j.jcms.2011.05.003","volume":"40","author":"S Otto","year":"2012","unstructured":"Otto S, Schreyer C, Hafner S, et al. Bisphosphonate-related osteonecrosis of the jaws\u2014characteristics, risk factors, clinical features, localization and impact on oncological treatment. J Craniomaxillofac Surg. 2012;40:303\u20139.","journal-title":"J Craniomaxillofac Surg"},{"key":"188_CR26","first-page":"1741","volume":"16","author":"A Agrillo","year":"2012","unstructured":"Agrillo A, Filiaci F, Ramieri V, et al. Bisphosphonate-related osteonecrosis of the jaw (BRONJ): 5 year experience in the treatment of 131 cases with ozone therapy. Eur Rev Med Pharmacol Sci. 2012;16:1741\u20137.","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"188_CR27","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1136\/jcp.36.10.1102","volume":"36","author":"A Dayas","year":"1983","unstructured":"Dayas A, Boughton BJ, Das BC. Ozone killing action against bacterial and fungal species; microbiological testing of a domestic ozone generator. J Clin Pathol. 1983;36:1102\u20134.","journal-title":"J Clin Pathol"},{"key":"188_CR28","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1111\/j.1600-0722.2007.00418.x","volume":"115","author":"P Muller","year":"2007","unstructured":"Muller P, Guggenheim B, Shmidlin P. Efficacy of gasiform ozone and photodynamic therapy on a multispecies oral biofilm in vitro. Eur J Oral Sci. 2007;115:77\u201380.","journal-title":"Eur J Oral Sci"},{"key":"188_CR29","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1080\/0962935062000197083","volume":"13","author":"V Bocci","year":"2004","unstructured":"Bocci V. Ozone as Janus: this controversial gas can be either toxic or medically useful. Mediat Inflamm. 2004;13:3\u201311.","journal-title":"Mediat Inflamm"}],"container-title":["International Journal of Implant Dentistry"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40729-019-0188-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s40729-019-0188-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40729-019-0188-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,29]],"date-time":"2020-09-29T23:09:22Z","timestamp":1601420962000},"score":1,"resource":{"primary":{"URL":"https:\/\/journalimplantdent.springeropen.com\/articles\/10.1186\/s40729-019-0188-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,1]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["188"],"URL":"https:\/\/doi.org\/10.1186\/s40729-019-0188-0","relation":{},"ISSN":["2198-4034"],"issn-type":[{"value":"2198-4034","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10,1]]},"assertion":[{"value":"1 July 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 August 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 October 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The requirements of the Helsinki Declaration were observed, and the patient gave informed consent for all surgical procedures.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained from the patient for the publication of this report and all accompanying images.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Gustavo Maluf, Rog\u00e9rio Jardim Caldas, Eduardo Rodrigues Fregnani, and Paulo S\u00e9rgio da Silva Santos declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"34"}}